CX-4945
Updated: Nov 14, 2009
| Brand Name: | |
| Generic Name: | |
| Code Name: | CX-4945 |
| Company: | Cylene |
| FDA Clinical Phase: | 1 |
Description:
CX-4945 is an oral anti-cancer agent. It inhibits CK2, an enzyme that plays a role in the development of cancerous cells through cellular processes such as cell cycle regulation, cellular signaling, blood vessel formation, inflammation, and cellular proliferation.
Clinical Trials:
For a list of clinical trials studying CX-4945 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Source: Cylene Pharmaceuticals, http://www.cylenepharma.com/cylene/cx_4945 (as of November 14, 2009)
Related Articles:
- Phase 1 Clinical Trial Of CX-4945 Begins In Cancer Patients
- New Myeloma Drugs Target Different Mechanisms: Signaling Pathways
- Gene Identification Could Lead To Better Treatment Options For Multiple Myeloma
- Novel Therapies For Myeloma Bone Disease
- New Advances In Myeloma Vaccines – Part 2: Types Of Potential Myeloma Therapeutic Vaccines
Leave a comment